Cathy Thut is Chief Business Officer at GentiBio. Prior to joining the company, Cathy was the CEO of Makana Therapeutics, a preclinical stage company aimed at alleviating the organ shortage crisis though xenotransplantation and led the merger of Makana with Recombinetics to combine the company’s xenotransplantation expertise with Recombinetics’ expertise in genetic engineering and swine husbandry. Prior to Makana, Cathy was Executive Director in the Business Development and Licensing group at Novartis Institutes for BioMedical Research (NIBR), where she worked across multiple therapeutic areas and was responsible for negotiating a number of NIBR’s immuno-oncology partnerships. In 2001, she joined Merck Research Laboratories in West Point, PA, to focus on ocular therapeutics and held positions of increasing responsibility including Therapeutic Area Group leader for Ophthalmology Research. Cathy did her graduate and postdoctoral training at U.C. Berkeley and Stanford University Medical School, respectively, and earned her MBA from MIT’s Sloan School of Management. In her spare time, Cathy enjoys baking cakes and pastry and daydreams of owning a patisserie one day.
Catherine Thut, PhD, MBA
Chief Business Officer